Adma Biologics (ADMA) Short term Debt (2025)
Adma Biologics (ADMA) posted Short term Debt of $2.8 million for Q4 2025, up 20.01% on a QoQ basis from $2.3 million in Q3 2025.
Adma Biologics (ADMA) Short term Debt (2025) Analysis & Trends
Adma Biologics' Short term Debt history runs 1 years deep, the most recent figure standing at $2.8 million for Q4 2025.
- Quarterly Short term Debt changed N/A year-over-year to $2.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.8 million (changed N/A YoY) and the FY2025 annual result came in at $2.8 million, changed N/A from the prior year.
- Short term Debt was $2.8 million for Q4 2025 at Adma Biologics, up from $2.3 million in the prior quarter.
- Across five years, Short term Debt topped out at $2.8 million in Q4 2025 and bottomed at $2.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Adma Biologics | 1.99 Bn | 1.91 Bn | 88.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.81 Mn |
| Sep 30, 2025 | 2.34 Mn |